| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Thyroxine | FAERS: 2 | US FAERS | |
| 2 | Dabigatran | FAERS: 1 | US FAERS | |
| 3 | Docetaxel | FAERS: 1 | US FAERS | |
| 4 | Gefitinib | FAERS: 1 | US FAERS | |
| 5 | Lapatinib | FAERS: 1 | US FAERS | |
| 6 | Mesalamine | FAERS: 1 | US FAERS | |
| 7 | N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide | FAERS: 1 | US FAERS | |
| 8 | Norgestrel | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 9 | Testosterone | FAERS: 1 | US FAERS | |
| 10 | Thyroxine | FAERS: 1 | US FAERS | |
| 11 | acalabrutinib | FAERS: 1 | US FAERS | |
| 12 | niraparib | FAERS: 1 | US FAERS | |
| 13 | semaglutide | FAERS: 1 | US FAERS | |
| 14 | teriflunomide | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120326
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.